- Home
- NUVL vs UBSI Comparison
NUVL vs UBSI Comparison
Compare NUVL & UBSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- UBSI
- Stock Information
- Founded
- NUVL 2017
- UBSI 1982
- Country
- NUVL United States
- UBSI United States
- Employees
- NUVL N/A
- UBSI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- UBSI Major Banks
- Sector
- NUVL Health Care
- UBSI Finance
- Exchange
- NUVL Nasdaq
- UBSI Nasdaq
- Market Cap
- NUVL 5.6B
- UBSI 4.9B
- IPO Year
- NUVL 2021
- UBSI N/A
- Fundamental
- Price
- NUVL $70.46
- UBSI $34.71
- Analyst Decision
- NUVL Strong Buy
- UBSI Hold
- Analyst Count
- NUVL 10
- UBSI 4
- Target Price
- NUVL $113.10
- UBSI $41.38
- AVG Volume (30 Days)
- NUVL 594.2K
- UBSI 867.0K
- Earning Date
- NUVL 05-08-2025
- UBSI 04-24-2025
- Dividend Yield
- NUVL N/A
- UBSI 4.26%
- EPS Growth
- NUVL N/A
- UBSI 1.48
- EPS
- NUVL N/A
- UBSI 2.75
- Revenue
- NUVL N/A
- UBSI $1,009,610,000.00
- Revenue This Year
- NUVL N/A
- UBSI $18.16
- Revenue Next Year
- NUVL N/A
- UBSI $6.12
- P/E Ratio
- NUVL N/A
- UBSI $12.62
- Revenue Growth
- NUVL N/A
- UBSI N/A
- 52 Week Low
- NUVL $61.80
- UBSI $30.68
- 52 Week High
- NUVL $113.51
- UBSI $44.43
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- UBSI 44.15
- Support Level
- NUVL $67.47
- UBSI $33.92
- Resistance Level
- NUVL $77.93
- UBSI $35.64
- Average True Range (ATR)
- NUVL 3.15
- UBSI 0.68
- MACD
- NUVL -0.44
- UBSI 0.09
- Stochastic Oscillator
- NUVL 26.88
- UBSI 47.46
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.